{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:13Z","timestamp":1789450453591,"version":"build-2803163510"},"reference-count":66,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1984,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p>The human immunodeficiency virus (HIV) was discovered in 1982, but treatment strategies were not introduced until 5 years later. Early regimens consisted of one or two drugs and often led to treatment failure. Since the advent in 1995 of highly active antiretroviral therapy (HAART), which consists of at least three agents, a dramatic improvement has been seen in the number of patients attaining undetectable viral loads, improved CD4 counts, and improved survival. However, early HAART often consisted of drugs with complex dosing schedules, strict food requirements, treatment\u2010limiting adverse effects, and the need to take 16\u201320 pills\/day. These treatment barriers often led to patient nonadherence, with subsequent treatment failure and development of resistant strains. The CD4 count and viral load are the most important surrogate markers used to determine if treatment is indicated. Current guidelines suggest starting treatment in patients who are symptomatic with an acquired immunodeficiency syndrome\u2013defining illness regardless of CD4 count or viral load, as well as in asymptomatic patients with a CD4 count of 350 cells\/mm<jats:sup>3<\/jats:sup> or below. In patients with CD4 counts above 350 cells\/mm<jats:sup>3<\/jats:sup> and viral loads above 100,000 copies\/ml, some clinicians prefer to defer treatment, whereas others will consider starting therapy; treatment is deferred in patients with CD4 counts above 350 cells\/mm<jats:sup>3<\/jats:sup> and viral load s below 100,000 copies\/ml. If therapy is started, the selection of appropriate agents is based on comorbidities (liver disease, depression, cardiovascular disease), pregnancy status, adherence potential (dosage regimen, pill burden, dosing frequency), food restrictions (dosing with regard to meals), adverse drug effects, and potential drug\u2010drug interactions. Within the last 8 years, newer antiretroviral agents have focused on ways to improve adherence, such as convenient dosing (fewer pills), pharmacokinetic and formulation changes to reduce dosing frequency or pill burden, and coformulated dosage forms that contain two or three drugs in one convenient pill. Other improvements include increased potency of newer agents, agents sensitive to a highly resistant virus, improved adverse\u2010effect profile (e.g., less gastrointestinal effects, improved lipid profiles), as well as protease inhibitor boosting with ritonavir, which takes advantage of the potent cytochrome P450 inhibitory action of ritonavir. This review focuses on the concepts of antiretroviral therapy, barriers to successful antiretroviral treatment, developments to limit treatment barriers, and new drug entities for the treatment of HIV.<\/jats:p>","DOI":"10.1592\/phco.26.8.1111","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T07:57:35Z","timestamp":1153814255000},"page":"1111-1133","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["An Update and Review of Antiretroviral Therapy"],"prefix":"10.1002","volume":"26","author":[{"given":"Frank J.","family":"Piacenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"U.S. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV\u20101 infected adults and adolescents. Available fromhttp:www.aidsinfo.nih.gov. Accessed May 10 2006."},{"key":"e_1_2_1_3_2","unstructured":"U.S. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Recommendations for use of antretroviral drugs in pregnant HIV\u20101 infected women for maternal health and interventions to reduce perinatal HIV\u20101 transmission in the United States. Available fromhttp:www.aidsinfo.nih.gov. Accessed April 25 2005."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000180095.12276.ac"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/431682"},{"issue":"1","key":"e_1_2_1_6_2","first-page":"S1","article-title":"Current perspectives on the nucleoside\/nucleotide components of combination antiretroviral therapy","volume":"37","author":"Piliero P.J.","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_1_7_2","first-page":"1","volume-title":"Business Briefing: Long\u2010Term Healthcare","author":"Negredo E.","year":"2004"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.6.3871-3877.2003"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.992-1003.2004"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/432619"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C388"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443090-00003"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.191"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1907-1914.2005"},{"key":"e_1_2_1_16_2","unstructured":"Kearney B.P. Damle B. Plummer A. Namini H. Ryan K. Cheng A..Pharmacokinetic evaluation of tenofovir DF and entericcoated didanosine. Presented at the 6th international congress on drug therapy in HIV infection Glasgow United Kingdom November 1721 2002."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200110010-00006"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D302"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.180"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363220-00003"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00100.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200411190-00007"},{"key":"e_1_2_1_23_2","volume-title":"Truvada (emtricitabine and tenofovir) package insert","author":"Gilead Sciences, Inc.","year":"2004"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464180-00005"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.251"},{"key":"e_1_2_1_26_2","volume-title":"Interim 24\u2010week data from study 934 comparing a regimen of Viread and Emtriva versus Combivir, both in combination with Efavirenz, in patients with HIV [press release]","year":"2004"},{"key":"e_1_2_1_27_2","unstructured":"Gathe J. Podzamczer D. Johnson M. et al.Once\u2010daily vs twice\u2010daily lopinavir\/ritonavir in antiretroviral\u2010na\u00efve patients: 48 weeks results. Presented at the 11th conference on retroviruses and opportunistic infections San Francisco CA February 811 2004."},{"key":"e_1_2_1_28_2","first-page":"H\u20101137c","volume-title":"The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs fixed dose zidovudine\/lamivudine and EFV in antiretroviral\u2010na\u00efve patients: a 24\u2010week preliminary analysis [abstr]","author":"Gazzard B.","year":"2004"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00010"},{"key":"e_1_2_1_30_2","volume-title":"Epzicom (abacavir and lamivudine) package insert","author":"GlaxoSmithKline","year":"2004"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200401010-00003"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403050-00009"},{"key":"e_1_2_1_33_2","volume-title":"Data on file","author":"GlaxoSmithKline","year":"2005"},{"key":"e_1_2_1_34_2","first-page":"1722b","volume-title":"Abacavir once daily plus lamivudine in combination with efavirenz is well\u2010tolerated and effective in the treatment of antiretroviral therapy\u2013na\u00efve adults with HIV\u20101 infection (ZODIAC study: CNA30021) [abstr]","author":"Gazzard B.G.","year":"2003"},{"key":"e_1_2_1_35_2","first-page":"H\u2010446","volume-title":"Abacavir (300 mg) BID vs zidovudine (300 mg) BID and efavirenz (600 mg) QD in HIV\u20101 infected, antiretroviral\u2010na\u00efve adults: CNA30024, 48\u2010week final results [abstr]","author":"DeJesus E.","year":"2003"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00014"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363150-00009"},{"key":"e_1_2_1_38_2","volume-title":"Aptivus (tipranavir) package insert","author":"Boehringer Ingelheim","year":"2005"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2005.19.58"},{"key":"e_1_2_1_40_2","first-page":"H\u20101137a","volume-title":"RESIST\u20101: a phase 3, randomized, controlled, open\u2010label, multicenter trial comparing tipranavir\/ritonavir to an optimized comparator protease inhibitor\/r regimen in antiretroviral experienced patients: 24\u2010week data [abstr]","author":"Hicks C.","year":"2004"},{"key":"e_1_2_1_41_2","unstructured":"Schapiro J. Cahn P. Trottier B. et al.Effect of baseline genotype on response to tipranavir\/ritonavir compared with standard of care comparator in treatment experienced patients: the phase 3 RESIST\u20101 and 2 trials. Presented at the 12th conference on retroviruses and opportunistic infections Boston MA February 2225 2005."},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2005.19.67"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464180-00014"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1089\/108729103322555944"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D394"},{"key":"e_1_2_1_46_2","first-page":"A\u20101616","volume-title":"PK of once daily Reyataz, DDI\u2010EC, tenofovir [poster]","author":"Kaul S.","year":"2003"},{"key":"e_1_2_1_47_2","volume-title":"Important new pharmacokinetic data for Reyataz (atazanavir) in combination with Viread (tenofovir disoproxil fumarate) [press release]","year":"2003"},{"key":"e_1_2_1_48_2","volume-title":"Reyataz (atazanavir) package insert","author":"Bristol\u2010Myers Squibb Company","year":"2004"},{"key":"e_1_2_1_49_2","volume-title":"Clinical pharmacology of HIV therapy","author":"Phair J.P.","year":"2005"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/108729104323038874"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/420932"},{"key":"e_1_2_1_52_2","unstructured":"Nieto\u2010Cisneros L. Zala C. Fessel W.J. et al.Antiviral efficacy metabolic changes and safety of atazanavir versus lopinavir\/ritonavir in combination with 2 NRTI's in patients who have experienced virologic failure with prior PI\u2010containing regimens: 24 week results from BMS AI424\u2013043. Presented at the 2nd International AIDS Society conference on HIV pathogenesis and treatment Paris France July 1316 2003."},{"key":"e_1_2_1_53_2","unstructured":"Lichtenstein K. Clumeck N. Belios N. et al.Lipid benefits are observed in antiretroviral\u2010experienced HIV\u2010infected patients when switched to atazanavir\u2010containing regimens. Presented at the 2nd International AIDS Society conference on HIV pathogenesis and treatment Paris France July 1316 2003."},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200406010-00005"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D143"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1086\/378302"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200402000-00003"},{"key":"e_1_2_1_60_2","unstructured":"Mascolini M for the National AIDS Treatment Advocacy Project.ICAAC ART report: new HIV drugs\u2010tipranavir\/r; reverset; GSK CCR5 inhibitor 140 news on new(er) antiretroviral. Report 4 from the 14th interscience conference on antimicrobial agents and chemotherapy. Washington DC October 30November 2 2004."},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200312050-00001"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200406180-00008"},{"key":"e_1_2_1_63_2","unstructured":"Bethell R. Adams J. DeMuys J. et al.Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. Presented at the 11th conference on retroviruses and opportunistic infections San Francisco CA February 811 2004."},{"key":"e_1_2_1_64_2","unstructured":"Murphy R.L. Schurmann D. Beard A. et al.Potent anti\u2010HIV\u20101 activity of reverset following 10 days of monotherapy in treatment\u2010na\u00efve individuals. Presented at the XV international AIDS conference Bangkok Thailand July 1116 2004."},{"key":"e_1_2_1_65_2","unstructured":"Katlama C. Berger D. Bellos N. et al.Efficacy of TMC114\/r in 3\u2010class\u2010experienced patients with limited treatment options: 24\u2010week planned interim analysis of 2 96\u2010week multinational dose\u2010finding trials. Presented at the 12th conference on retroviruses and opportunistic infections Boston MA February 2225 2005."},{"key":"e_1_2_1_66_2","unstructured":"Olson W. Israel R. Jacobson J. et al.Viral resistance and pharmacologic analysis of phase I\/II study patients treated with HIV\u20101 entry inhibitor PRO 542. Presented at the 10th conference on retroviruses and opportunistic infections Boston MA February 1014 2003."},{"key":"e_1_2_1_67_2","unstructured":"Martin D. Jacobson J. Schurmann D. et al.PA\u2010457 the first\u2010in\u2010class maturation inhibitor exhibits antiviral activity following a single dose in HIV\u20101 infected patients. Presented at the 12th conference on retroviruses and opportunistic infections Boston MA February 2225 2005."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.8.1111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.8.1111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:32:23Z","timestamp":1761057143000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.8.1111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1592\/phco.26.8.1111"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.8.1111","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}